Claude Surpasses ChatGPT in App Store Downloads Amid Pentagon Controversy
Anthropic’s Claude has risen to the number one spot among free apps in Apple’s U.S. App Store, surpassing OpenAI’s ChatGPT. Google’s Gemini currently ranks lower in downloads. This shift in the AI chatbot landscape comes as public scrutiny intensifies regarding AI partnerships with governments and the ethical implications of AI deployment.
Why Claude Jumped to the Top of the Apple Store
Claude’s surge in popularity follows OpenAI’s announcement of a collaboration with the U.S. Department of Defense to integrate artificial intelligence systems into classified networks. This decision sparked considerable debate, particularly after Anthropic CEO Dario Amodei voiced public concerns about the potential risks of AI being used for mass surveillance or the development of fully autonomous weapons Mashable.
In response to the broader discussion, over 700 employees from major AI companies reportedly signed an open letter advocating for caution in government AI deployment, specifically concerning surveillance and lethal autonomy Mashable.
The timing of these events coincided with Claude’s ascent in the App Store rankings.
Claude Achieved Rapid Growth in Users
According to Anthropic, the company has experienced significant user growth in recent months:
- Free users increased by more than 60% since January.
- Daily signups have tripled since November.
- Paid subscribers have more than doubled this year.
The app’s ranking improved from #42 before Super Bowl LX to the top 10 and ultimately to #1.
What Claude’s Surge Means for the AI Race
Even as App Store rankings are subject to change, the speed of Claude’s climb suggests a growing public interest in AI platforms that prioritize ethical considerations. ChatGPT remains a widely used AI tool, and Gemini continues to expand within Google’s ecosystem Business Insider. Yet, Claude’s temporary lead demonstrates the impact of ethical positioning, partnerships, and public messaging on user behavior in the competitive AI market.
As AI platforms become increasingly integrated with government, enterprise, and defense contracts, public trust is likely to play a crucial role in determining which services users choose to adopt Mashable.
Recent Developments
On March 1, 2026, Claude reached the No. 1 spot in U.S. App downloads, with ChatGPT in second place and Google’s Gemini in fourth Axios. This change followed a controversial announcement by OpenAI CEO Sam Altman regarding collaboration with the Department of Defense Reddit.
Former President Donald Trump criticized Anthropic’s stance on government AI use, calling it a “DISASTROUS MISTAKE” on his Truth Social platform Mashable.
Keep reading
- Microsoft Releases AI Code of Conduct to Ensure Human Control
- First-Ever Adult T. Rex Trackway Discovered in North Dakota
- Shift Supervisor Job at CVS Health – Bristol, Rhode Island (news-usa.today)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)